Attached files

file filename
EX-32.2 - EX-32.2 - ReShape Lifesciences Inc.rsls-20170930ex3222f9064.htm
EX-31.2 - EX-31.2 - ReShape Lifesciences Inc.rsls-20170930ex312436acc.htm
EX-31.1 - EX-31.1 - ReShape Lifesciences Inc.rsls-20170930ex311c0f878.htm
EX-10.6 - EX-10.6 - ReShape Lifesciences Inc.rsls-20170930ex1064088b1.htm
EX-10.5 - EX-10.5 - ReShape Lifesciences Inc.rsls-20170930ex105555fdb.htm
EX-10.4 - EX-10.4 - ReShape Lifesciences Inc.rsls-20170930ex104f83d96.htm
10-Q - 10-Q - ReShape Lifesciences Inc.rsls-20170930x10q.htm

 

 

Exhibit 32.1

 

CERTIFICATION

 

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Dan W. Gladney, in his capacity as Chief Executive Officer of ReShape Lifesciences Inc., hereby certifies that, to the best of his knowledge:

 

1.

1.The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 to which this Certification is attached as Exhibit 32.1 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

 

2.

2. The information contained in the Report fairly presents, in all material respects, the financial condition and the results of operations of ReShape Lifesciences Inc. as of, and for, the periods covered by the Report.

 

 

 

 

By:

/S/ DAN W. GLADNEY

 

 

Dan W. Gladney

 

 

President and Chief Executive Officer

 

Date:  November 14, 2017